Therapeutic Efficacy of Shenmai Injection As an Adjuvant Treatment in Dilated Cardiomyopathy: A Protocol for Systematic Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Feb 22

PMID 32080094

Authors

Kai Gao

Yan-Ping Song

Anna Song

Hao Chen

Lin-Tao Zhao

Hai-Wang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Shenmai injection (SMI) is a Traditional Chinese Medicine patent prescription consisting of extractions from ophiopogonis radix and ginseng radix rubra. Clinical studies showed that SMI combined with conventional medicine treatment (CMT) can enhance the therapeutic efficacy for dilated cardiomyopathy (DCM). However, there is still a lack of comprehensive and systematic evidence, which urgently requires us to verify its therapeutic efficacy. Hence, we provide a protocol for systematic review and meta-analysis.

Methods: The systematic search on the MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang database, VIP database, the Cochrane Library, Embase and Chinese Biomedical Database (CBM) in Chinese and English language with dates ranging from the earliest record to August 8, 2019. Next, the quality of each trial was assessed according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. Then, the outcome data were recorded and pooled by RevMan 5.3 software.

Results: The systematic review and meta-analysis aims to review and pool current clinical outcomes of SMI for the adjuvant treatment of DCM.

Conclusion: This study will provide a high-quality evidence of SMI for the adjuvant treatment on DCM patients.

Prospero Registration Number: CRD42019146369.

References

Liu W, Zhang J, Yao X, Jiang C, He J, Ni P . Shenmai injection enhances the cytotoxicity of chemotherapeutic drugs against colorectal cancers via improving their subcellular distribution. Acta Pharmacol Sin. 2016; 38(2):264-276. PMC: 5309759. DOI: 10.1038/aps.2016.99. View

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

Harbord R, Egger M, Sterne J . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2005; 25(20):3443-57. DOI: 10.1002/sim.2380. View

Merlo M, Cannata A, Vitagliano A, Zambon E, Lardieri G, Sinagra G . Clinical management of dilated cardiomyopathy: current knowledge and future perspectives. Expert Rev Cardiovasc Ther. 2015; 14(2):137-40. DOI: 10.1586/14779072.2016.1125292. View

Tang W, Huang Y . Cardiotonic modulation in heart failure: insights from traditional Chinese medicine. J Am Coll Cardiol. 2013; 62(12):1073-1074. PMC: 4024708. DOI: 10.1016/j.jacc.2013.05.028. View

McKenna W, Maron B, Thiene G . Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res. 2017; 121(7):722-730. DOI: 10.1161/CIRCRESAHA.117.309711. View

Sisakian H . Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol. 2014; 6(6):478-94. PMC: 4072838. DOI: 10.4330/wjc.v6.i6.478. View

Zhu Y, Li Y, Ju J, Du F, Zang Y, Wang X . Oral Chinese Herbal Medicine for Treatment of Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2016; 2016:1819794. PMC: 5007314. DOI: 10.1155/2016/1819794. View

Li J, Wang H, Li S, Yu X, Wang Z . Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complement Med. 2011; 17(7):579-87. DOI: 10.1089/acm.2010.0354. View

10.

Ma B, Niu X, Wang M . [Effect of shenmai injection on immunologic function in patients with dilated cardiomyopathy]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005; 25(4):320-3. View

11.

Towbin J, Lowe A, Colan S, Sleeper L, Orav E, Clunie S . Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006; 296(15):1867-76. DOI: 10.1001/jama.296.15.1867. View

12.

Jefferies J, Towbin J . Dilated cardiomyopathy. Lancet. 2010; 375(9716):752-62. DOI: 10.1016/S0140-6736(09)62023-7. View

13.

Zhou Y, Zhao B, Wu W, Yang X, Long S, Deng H . Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial. Trials. 2018; 19(1):474. PMC: 6123916. DOI: 10.1186/s13063-018-2845-7. View

14.

Xian S, Yang Z, Lee J, Jiang Z, Ye X, Luo L . A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. J Ethnopharmacol. 2016; 186:136-142. DOI: 10.1016/j.jep.2016.03.066. View

15.

Lu L, Zheng G, Wang Y . An overview of systematic reviews of shenmai injection for healthcare. Evid Based Complement Alternat Med. 2014; 2014:840650. PMC: 3942339. DOI: 10.1155/2014/840650. View

16.

Verdonschot J, Hazebroek M, Ware J, Prasad S, Heymans S . Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. J Am Heart Assoc. 2019; 8(11):e012514. PMC: 6585365. DOI: 10.1161/JAHA.119.012514. View

17.

Wang K, Wu J, Duan X, Zhang D, Lin X, Zhang S . Comparative efficacy of Chinese herbal injections for angina pectoris: A Bayesian network meta-analysis of randomized controlled trials. Complement Ther Med. 2019; 43:208-217. DOI: 10.1016/j.ctim.2019.01.019. View

18.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Colvin M . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society.... Circulation. 2017; 136(6):e137-e161. DOI: 10.1161/CIR.0000000000000509. View

19.

Soares P, Rocha G, Pissarra S, Soares H, Flor-de-Lima F, Costa S . Neonatal dilated cardiomyopathy. Rev Port Cardiol. 2017; 36(3):201-214. DOI: 10.1016/j.repc.2016.10.007. View

20.

Vrtovec B . Cell Therapy for Nonischemic Cardiomyopathy: Current Status and Future Perspectives. Circ Res. 2018; 122(1):28-30. DOI: 10.1161/CIRCRESAHA.117.312385. View